Deregulation of the Rb and p53 pathways in uveal melanoma

被引:85
|
作者
Brantley, MA
Harbour, JW
机构
[1] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA
[2] Washington Univ, Div Mol Oncol, St Louis, MO 63110 USA
来源
AMERICAN JOURNAL OF PATHOLOGY | 2000年 / 157卷 / 06期
关键词
D O I
10.1016/S0002-9440(10)64817-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Uveal melanoma is the most common primary eye cancer, yet its molecular pathogenesis is poorly understood. In this study, we investigated the immunohistochemical expression of proteins in the Rb and p53 tumor suppressor pathways in 33 uveal melanomas from enucleated eyes. Strong nuclear staining for Rb was present in most tumors. However, a few cases displayed weak nuclear staining and strong cytoplasmic staining (possibly indicating Rb mutation), and this aberrant staining correlated strongly with failed radiotherapy or thermotherapy before enucleation. Staining for cyclin D1 was positive in most tumors and was associated with advanced age and larger tumor size, which are both poor prognostic factors. Generally, immunostaining for p53 was weak (suggesting a lack of p53 mutations), although p53 positivity correlated strongly with staining for phosphorylated Rb, supporting the notion that inappropriate phosphorylation of Rb can induce p53, Strong immunostaining for MDM2, which can functionally block p53 activity, was observed in most tumors and correlated significantly with female sex. Strong cytoplasmic staining was observed for Bc12, which can inhibit both p53-dependent and -independent apoptosis, We conclude that Rb and p53 are mutated infrequently in uveal melanoma, but their respective pathways may be functionally inactivated.
引用
收藏
页码:1795 / 1801
页数:7
相关论文
共 50 条
  • [41] SUPPRESSOR GENES OF RB AND P53 TUMORS
    MAY, P
    BULLETIN DU CANCER, 1993, 80 (08) : 690 - 692
  • [42] c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma
    Chana, JS
    Wilson, GD
    Cree, IA
    Alexander, RA
    Myatt, N
    Neale, M
    Foss, AJE
    Hungerford, JL
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1999, 83 (01) : 110 - 114
  • [43] Characterizing the role of the p53 effector PERP in cell migration: Insights from uveal melanoma cells
    Awais, Raheela
    Davies, Lyndsay
    Paraoan, Luminita
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [44] p53 Regulation of Metabolic Pathways
    Gottlieb, Eyal
    Vousden, Karen H.
    COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2010, 2 (04): : a001040
  • [45] Deconstructing p53 pathways in vivo
    Brady, Colleen A.
    Broz, Daniela Kenzelmann
    Jiang, Dadi
    Mello, Stephano Spano
    Bieging, Kathryn
    Johnson, Thomas M.
    Jarvis, Leslie A.
    Kozak, Margaret M.
    Basak, Shashwati
    Attardi, Laura D.
    CANCER RESEARCH, 2013, 73
  • [46] Mathematical Modeling of p53 Pathways
    Kim, Eunjung
    Kim, Jae-Young
    Lee, Joo-Yong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (20)
  • [47] Ceramide Signaling and p53 Pathways
    Jeffries, Kristen A.
    Krupenko, Natalia I.
    SPHINGOLIPIDS IN CANCER, 2018, 140 : 191 - 215
  • [48] Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis
    Ferguson, Blake
    Muller, H. Konrad
    Handoko, Herlina Y.
    Khosrotehrani, Kiarash
    Beermann, Friedrich
    Hacker, Elke
    Soyer, H. Peter
    Bosenberg, Marcus
    Walker, Graeme J.
    PIGMENT CELL & MELANOMA RESEARCH, 2010, 23 (06) : 771 - 780
  • [49] P53 Isoforms deregulation in the Ovarial carcinoma -: Clinical relevance
    Hofstetter, G.
    Schuster, E.
    Berger, A.
    Seeber, J.
    Wolf, A.
    Reimer, D.
    Daxenbichler, G.
    Mueller-Holzner, E.
    Reinthaller, A.
    Marth, C.
    Zeimet, A. G.
    Zeillinger, R.
    Concin, N.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (04) : 433 - 433
  • [50] The RB (pRb2/p16) and p53 (p14/p53/p21) Tumor-suppressor Pathways in Endemic Burkitt Lymphoma
    Kalungi, Sam
    Wabinga, Henry
    Bostad, Leif
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (02) : E54 - E59